HWHG(SH:600079) Xin Lang Cai Jing·2025-11-21 08:03Core Viewpoint - The company has received acceptance for the drug registration application of Dexamfetamine Mesylate Capsules, which is currently not available in the domestic market, indicating a potential expansion of its product line and market competitiveness [1] Group 1: Company Developments - The company's subsidiary, Yichang Renfu Pharmaceutical Co., Ltd., has received the acceptance notice from the National Medical Products Administration for the drug registration application [1] - The drug is intended for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in adults and pediatric patients aged 6 and above [1] - The total R&D investment in this project amounts to approximately 90 million RMB [1] Group 2: Market Implications - The acceptance of the drug registration application marks the entry of the product into the review phase, which, if successfully approved, will enhance the company's product offerings [1] - Currently, there are no similar products approved for sale or import in the domestic market, indicating a unique market opportunity for the company [1]